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The known effects ofcalcium channel blockers on various aspects of potassium homeostasis
are reviewed. Regulation ofpotassium homeostasis requires both renal and extrarenal handling
mechanisms. Signaling by calcium appears to mediate both of these. Calcium channels have
been identified in adrenal glomerulosa cells, and cellular calcium entry has been demonstrated
in vitro to be necessary for the synthesis and secretion of aldosterone. Calcium channel
antagonists such as verapamil and nifedipine, at pharmacologic doses, can block aldosterone
production. In vivo, however, only chronic administration of verapamil appears to attenuate
aldosterone responsiveness to angiotensin II. Chronic administration of nifedipine does not
have a dramatic effect on aldosterone production following potassium loading. Other studies
have demonstrated improved extrarenal potassium disposal following treatment with calcium
channel blocking agents. Clinically, there are no reports ofeither hyperkalemia or hypokalemia
with the routine therapeutic use of these agents given alone. This review was prompted by the
development ofhyperkalemia in a patient with chronic renal failure following the initiation of
therapy with the calcium channel blocker diltiazem; however, numerous other etiologies may
also have contributed to the development of hyperkalemia in this case. Review of the data
indicates that current evidence implicating this class ofdrugs in the pathogenesis ofdisordered
potassium regulation remains equivocal.
INTRODUCTION
Calcium channel blockers are frequently prescribed in the management of hyper-
tension and coronary artery disease. Although their use is generally well tolerated,
numerous side effects havebeen described, most commonlyhemodynamic abnormal-
ities [1]. Metabolic disturbances have been only rarely described [12,13,14]. Re-
cently, a patient was seen in consultation after developing severe hyperkalemia
temporally related to the initiation of therapy with the calcium channel antagonist
diltiazem. This condition prompted us to review the effects of calcium channel
blockers on the pathogenesis ofdisorders ofpotassium regulation.
The patient was a 55-year-old male with a history of chronic renal failure and
squamous cell carcinoma of the mouth, admitted for evaluation of a thyroid mass.
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Surgical exploration revealed recurrent tumor. Pre-operatively, hewas noted to have
renal dysfunction with a baseline creatinine of 5 mg/dl and mild hyperkalemia with
serumpotassium concentrations 5.0-5.6mEq/l. Hispost-operative coursewasuncom-
plicated except for an acute increase in the serum potassium concentration to 6.0
mEq/l one day after diltiazem was begun for treatment of hypertension. He was
treated with sodium polystyrene sulfonate, and both enteral and intravenous sodium
intake was increased. Daily potassium excretion was 24 mEq despite good urine
output on a high sodium diet, and subsequent studies revealed that his serum
aldosterone concentration was markedly depressed at <2.5 ng/dl. The transtubular
potassium gradient (TTKG; see Appendix) was also markedly depressed at 2.3.
Hyperkalemia did not readily resolve despite discontinuation ofthe calcium channel
blockers but responded to pharmacologic concentrations of fludrocortisone, with a
significant reduction in serum K+ to 4.7 mEq/l and an increase in the TTKG to 5.2.
DISCUSSION
The etiology of the hyperkalemia in this case was most likely multifactorial. The
initial high potassiumvalueswere associated with a significant reduction in glomeru-
lar filtration. Underlying hypoaldosteronism was subsequently documented. Despite
these possible etiologies, the temporal relationship between the development of
hyperkalemia and the addition ofdiltiazem made us suspect a role ofthis agent in the
pathogenesis of this patient's disorder. This suspicion prompted a review of the
effects ofcalcium channel blockers on potassium homeostasis.
Calcium ChannelBlockers andAldosterone Biosynthesis: In Vitro Studies
Aldosterone is synthesized in the adrenal cortex by glomerulosa cells and its
production is stimulated by increases in plasma K+ concentration, angiotensin II
(All), and ACTH. The effects of ACTH are mediated via cyclic AMP, whereas All
and hyperkalemia mediate aldosterone biosynthesis through cAMP-independent
mechanisms.
The stimulation of aldosterone production or release by calcium has been inten-
sively investigated. Numerous studies have examined the role ofcalcium on aldoster-
one production in response to the three major stimuli. Fakunding and Catt [2] have
studied the in vitro effects of the calcium channel blockers lanthanum, a trivalent
metal cation, and verapamil on aldosterone production in isolated dog and rat
glomerulosa cells. When All and ACTHwere administered in maximally stimulating
doses in the presence of lanthanum, there was a rapid and progressive inhibition of
aldosterone production to both stimuli, although All was more sensitive than ACTH
to its effects. This inhibition was partially overcome when All and ACTH concentra-
tions were increased. Likewise, cAMP production was markedly diminished by
calcium channel blockade. Similar resultswere obtained when hyperkalemic stimula-
tion was employed, and, aswith their previous experiments, this inhibition was again
partially reversed by further increases in the extracellular K+ concentration. Aldo-
sterone production was similarly inhibited at verapamil concentrations of 10-6M,
with complete inhibition at approximately 10-4M. This effect was dependent on the
extracellular calcium concentration, and increasingthe extracellular calcium concen-
tration could partially overcome the inhibition at lower verapamil concentrations
(Fig. 1).
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nMangiotensin II. (From [2]; reprinted
_, , , withthe permission ofJohn L. Fakund-
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Additional in vitro studies were performed by Foster et al. [3], investigating
calcium uptake into bovine adrenal cells after stimulation by K+ and All. A
progressive increase in aldosterone production was observed following AII or K+
stimulation as a function of calcium concentration. Aldosterone production in-
creased progressively, with maximal stimulation at a calcium concentration of 0.5
mM. Likewise, incubation with A23187, a divalent ionophore, was associated with a
progressive increase in aldosterone production, whereas incubationwith methoxyve-
rapamil was associated with a progressive decline. They showed that All and K+
directly stimulate Ca uptake, and their results have been corroborated by others [4].
Patch clamp data using bovine adrenal glomerulosa cells have demonstrated the
presence of two types of calcium channels, which are identified by their patterns of
deactivation [5]. The "T-type" Ca channels activate slowly and inactivate rapidly
in response to strong depolarizations. The other type, the "L-type" Ca channel,
deactivates rapidly at more positive potentials. The T-type Ca channels were shown
to be primarily responsible for mediating the response to AII and elevated K+
concentrations. Activation ofthese channelsbyAll leads to calcium influxinto cells,
and nitrendipine was able to both block these channels and suppress aldosterone
secretion in response to both stimuli. Molecular events relating cellular calcium
entry and aldosterone biosynthesis are not yet clear. It is conceivable, however, that
calcium may act as an intracellular mediator ofenzyme activation.
Other potential mechanisms of inhibition of aldosterone synthesis by calcium
channelblockershaveonlyrecentlybecome understood (Fig. 2). Fakunding and Catt
[2] have demonstrated that verapamil nonspecifically inhibits biosynthesis at a step
precedingthe formation ofpregnenolone. Recently, however, Blanchouin-Emeric et
al. [6] have shown that verapamil also inhibits the synthesis of aldosterone from
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18-hydroxycorticosterone in such a way that it has no effect on cellular respiration
and without displacement of substrate from cytochrome P450 1113, which is known to
catalyze the conversion of18-hydroxycorticosterone to aldosterone. Inhibition at this
level occurred in the absence of the usual regulatory factors of aldosterone produc-
tion and was independent of calcium. While these studies clearly demonstrate the
dependence of aldosterone biosynthesis on calcium entry, the physiologic signifi-
cance of these findings is unclear, since the concentrations of calcium channel
blockers employed exceed those achieved in vivo by 1-2-log orders in magnitude
[20-26].
Effects ofCalcium ChannelBlockers onAldosterone Production: In Vivo Studies
In vivo studies in rats have investigated the role of calcium on plasma renin and
aldosterone production [7,8,9]. Ratsfed anormal NaCl diet showed augmentation of
aldosterone production in response to high CaCl2 intake, independent ofchanges in
plasma renin activity. On a low NaCl diet, CaCl2 ingestion was associated with a
twofold rise in aldosterone. The effects ofcalcium ingestion on parathyroid hormone
and vitamin D metabolism were not evaluated; thus, although direct effects ofthese
on aldosterone metabolism cannot be excluded, these experiments appear to corrob-
orate in vitro observations that Ca++ is a potent stimulus for aldosterone production.
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Renal hemodynamic effects of calcium blockers have also been studied. Kotchen
and Guthrie [7] showed that acute administration of verapamil, 4 ,ug/kg/minute to
uni-nephrectomized dogs was associated with abrupt suppression of renin secretion
but was unassociated with an effect on plasma aldosterone; however, chronic
verapamil administration in rats did suppressplasma aldosterone levels to 35 percent
ofcontrols when rats were maintained on a low-salt diet.
Kotchen and Guthrie [7] have also studied the effects of acute and chronic
verapamil administration on aldosterone responsiveness to graded intravenous
infusions of AII and ACTH in normal subjects. Subjects were loaded intravenously
with verapamil 8.5 mg and then maintained with a continuous infusion at 3.6
,ug/kg/minute. There were no changes in blood pressure, heart rate, plasma renin
activity (PRA), or plasma aldosterone. The pressor response to AII was prevented,
and no effect was observed with regard to the incremental increase in plasma
aldosterone in response to either AII or ACTH. Subsequently, the effects ofchronic
verapamil administration were evaluated. After five days of therapy with verapamil,
120 mg three times daily, both the pressor response and incremental rise in plasma
aldosterone in response to All were attenuated, although no significant differences
were noted in response to ACTH. In neither experiment was serum K+studied.
Recently, Favre et al. [12] have studied the effects of nifedipine on aldosterone
responsiveness to Na+ depletion and K+loading in humans. Healthyvolunteers were
maintained on a 15 mmol Na+, 100 mmol K+ diet and treatedwith dexamethasone to
suppress endogenous ACTH. Subjects were treated with either nifedipine 30 mg by
mouth or placebo, and they were infused with KCl, 0.6 mmol/kg, over two hours.
Baseline PRA was elevated in Na+-depleted subjects and was significantly increased
in nifedipine-treated patients. No changes were observed in plasma K+ in either
treatment group, and, despite that, a marked rise in plasma aldosterone was
observed (Fig. 3). Nifedipine-treated subjects achieved aldosterone levels similar to
that ofcontrols, but the response was delayed.
Clinically, the effects of calcium channel blockers on aldosterone production at
physiologic doses have been more difficult to demonstrate. Nadler et al. [10] used
nifedipine to treat ten patients with primary aldosteronism due to either idiopathic
hyperaldosteronism or adenomas. In this series, all patients showed a reduction in
plasma aldosterone levels, improvement in blood pressure, and normalization of
hyperkalemia. Bursztyn et al. [11] were, however, unable to demonstrate animprove-
ment in plasma aldosterone or hyperkalemia following similar treatment in two
patients with hyperaldosteronism due to adrenal adenoma. Larger studies will be
required to establish the efficacy of these agents in the treatment of hyperaldoste-
ronism.
In order to help further elucidate the clinical effects of calcium channel blockers
on serum K+, Kelleher and Gillum retrospectively examined the blood chemistry
values of 46 patients prior to and following initiation of nifedipine therapy [13].
Serum K+ increased significantly from 4.2 to 4.5 mEq/l; eight subjects developed
modest hyperkalemia (serum K+ > 5.0 mEq/l). Further examination showed, how-
ever, that development of significant elevations in serum K+ occurred only in those
patients concomitantly taking propranolol. Subjects with diabetes mellitus, renal
insufficiency, and obstructive uropathy as well as those receiving oral K+, K-sparing
diuretics, and non-steroidal anti-inflammatory drugs were excluded from analysis;
these patients represent a subgroup of patients who may be more sensitive to the
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FIG. 3. Effect of a two-hour KCl
intravenous infusion (0.6 mmollkg in 5
percent glucose) on plasma potassium
concentration, plasma renin activity,
and plasma aldosterone levels, in 11
healthy subjects during sodium restric-
tion. (From [12]; reprinted with the
permission ofMichel B. Vallotton.)
superimposition of other defects in K+ excretion. That patients treated simulta-
neously with beta-blockers and calcium channel antagonists developed significant
elevations in serum K+ supports the notion that concomitant defects in K+ handling
maymake one more susceptible to a second albeit mild defect. Furtherstudyofthese
higher-risk patients will be required to elucidate these issues. Hoyt [14] implicated
diltiazem in the development of hyperkalemia in one patient taking this agent for
management ofhypertension. His claim hasbeen disputed [15], as numerous factors,
including advanced age, exogenous potassium ingestion, beta-adrenergic blocker
ingestion, and mild renal insufficiency, may also have contributed.
Thus, it seems that although suppression of aldosterone production by calcium
channel blockers is readily observed in vitro, the physiologic consequences in vivo are
rare. Furthermore, their therapeutic benefits with regard to the treatment of
hyperaldosteronism remain controversial and require further study. Adverse clinical
sequelae have so far been most commonly observed in patients who are also using
beta-adrenergic blockers. Thus, it is possible that further studies will reveal that
calcium channel antagonists can contribute to hyperkalemia only in patients with a
predisposition for this problem, such as diabetics and patients with underlying renal
insufficiency. Since the inhibitory effects ofcalcium channel blockers on aldosterone
production in vitro have, however, been demonstrated at drug concentrations of
approximately 106-10-7 M,which is far in excessofthe serum drugconcentrations of
approximately 5 x 10' M achieved with the clinical use ofthese agents, it is unlikely
that the effects will become clinically significant.
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TABLE 1
Potential Effects ofCalcium Channel Blockers on K Balance
1. Data Demonstrating Effects Which Could Increase Serum K
Suppression ofaldosterone synthesis
In vitro: Verapamil and nifedipine decrease AII, ACTH, and K-induced aldosterone biosyn-
thesis [2,3,4,6]*
Large non-clinical doses used
In vivo: Chronicverapamil administration suppresses plasma aldosterone in salt-depleted rats
[91
Diminished aldosterone responsiveness to acute K+ load following chronicverapamil
administration (blunting oftime-response curve) [12]
Decreased aldosterone levels and improvement ofhyperkalemia in patients with
hyperaldosteronism [10], reports not subsequently confirmed [11]
Suppression ofaldosterone synthesis may impair extrarenal K disposal in dialysis pa-
tients [16]
2. Data DemonstratingEffects Which CouldReduce Serum K
Enhancement ofextrarenal K disposal in rats [17,19]
*References as listed
Effects ofCalcium ChannelBlockers on ExtrarenalK+ Handling
In addition to its well-known effect ofmodulating renal K+ excretion, aldosterone
may also play a role in mediating extrarenal K+ disposal. Sugarman and Brown [16]
examined the role ofaldosterone in modulating extrarenal K+ handling following 0.5
mEq/kg K+ loads in anephric humans. The serum K+ concentrations measured
following KCl infusion were significantly lower after treatment with the synthetic
mineralocorticoid deoxycorticosterone (DOCA, 10 mg intramuscularly daily) and
were higher inpatients treatedwith the mineralocorticoid antagonist spironolactone
when compared to controls. The volume of distribution of K+ was greater during
DOCA administration than that in controls or spironolactone-treated subjects, and
no changes were observed with regard to either fecal or salivary excretion. These
results suggest that mineralocorticoids, at least at pharmacologic doses, may aug-
ment K+ tolerance, presumablyby affecting transcellular shifts.
The effects ofcalcium channel blockers on extrarenal K+ handling have also been
studied by Sugarman and Kahn [17]. Both verapamil and nifedipine were shown to
blunt the rise in plasma K+ following KCl infusion into nephrectomized (NPX),
adrenalectomized (ADX) rats. Effects mediated by aldosterone, insulin, or the
sympatho-adrenergic system were excluded. They hypothesized that K+ transloca-
tion mayrelate to differences in regional blood flowor that diminished calcium influx
may, in some fashion, be linked to impairment of K+ efflux from the intracellular
fluid compartment (ICF). Because parathormone (PTH) had previouslybeen shown
to enhance cellular calcium uptake, further studies were performed to assess its role
in mediating extrarenal K+ disposal [18]. Extrarenal K+ handling was improved in
nephrectomized (NPX), parathyroidectomized (PTX) rats, whereas this function
wasimpaired following PTH administration. Soliman et al. [19] subsequently showed
that verapamil improves K+ disposal following PTH administration in adrenalecto-
mized, NPX, PTX rats, suggesting that cellular calcium influx may directly mediate
extrarenal K+ disposal.
These data exemplify the complexity of effects of calcium channel blockade on
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extrarenal K+ homeostasis (Table 1). Whereas direct inhibition of aldosterone
production by calcium channel blockers may impair translocation, impairment of
cellular calcium entry directly promotes extrarenal K+ disposal.
CONCLUSION
In summary, calcium channel blockers have two distinct effects on K+ homeostasis
(Table 1). Calcium is an important intracellular messenger for the synthesis and
secretion of aldosterone in response to All and K+ and is necessary for the activity
and production of cAMP in response to ACTH. Calcium channels have been
identified in glomerulosa cells, and, in vitro, aldosterone production is blocked by
calcium channel antagonists, at least at two sites. In vivo, however, only chronic
administration ofthese compounds is associatedwith any appreciable suppression of
aldosteroneproduction. In humans, chronicverapamil administration attenuates the
aldosterone responsiveness to All administration but not to ACTH. In response to
K+ loading, nifedipine-treated, salt-deprived subjects were still able to achieve the
same peak aldosterone levels, although there was a shift in the time-response curve
to the left. Experimental studies have also demonstrated an improvement in extra-
renal K+ disposal with calcium channel blockers; however, these findings have not
been confirmed clinically.
Initial reports demonstrating a reduction in aldosterone synthesis in patients with
hyperaldosteronism have not been confirmed, and adverse clinical sequelae with the
routine use ofthese drugs, with respect to K+ homeostasis, hasbeen rare. In addition
to the potential ability of these agents to mediate extrarenal K+ disposal, other
factors are probably contributing, including the inability to achieve therapeutic drug
levels with standard oral dosing to suppress aldosterone synthesis effectively in vivo,
and the effects ofother hormonal factors such as insulin, catecholamines, and atrial
natriuretic factor (ANF) that also mediate K+ tolerance.
The development of hyperkalemia in our patient had numerous potentially
contributing etiologies, including mild volume contraction (leading to low distal
tubular flow), chronic renal failure, and hypoaldosteronism. In view of the in vivo
data detailed above, it is unlikely that the nifedipine or diltiazem contributed to his
hyperkalemia. Furthermore, discontinuation of these calcium channel blocking
agents did not readily improve his hyperkalemia. Thus, the potential role of these
drugs in the development ofhyperkalemia remains speculative.
APPENDIX
The TTKG has been described in detailbyHalperin and others [27,28,29,30] as an
index ofK+ secretory activity in the cortical collecting tubule. This concept has been
employedclinicallyinorderto differentiate renalfromnon-renal causesofhyperkale-
mia. Briefly, the TTKG has been defined as UK X POSJ/UOSm X PK and relates the
urinary K+ to the serum K+ concentrations corrected formedullarywaterabsorption.
Thus, it is a measure of the ability of the distal tubule to secrete K+ against a
gradient. In sodium-replete patientswithintactantidiuretichormone (ADH) respon-
siveness, a TTKG <4 has been associated with reduced mineralocorticoid bio-
activity (i.e., either aldosterone deficiency or resistance to its effects). Regarding the
patient described herein, the initial TTKGwas 2.3, owing toboth decreased absolute
concentrations of aldosterone and to possible diminished aldosterone responsive-
ness related to significant renal insufficiency. These defects were partially overcome
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by treatment with pharmacologic doses offludrocortisone, which was associated with
a significant increase in the TTKG.
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